San Diego, CA, United States of America

Mark S Tichenor

This inventor holds 26 USPTO granted patents and 8 published patent applications, plus 4 CIPO patents and 5 EPO patents, primarily in Kinase Inhibitors. Top assignees: Janssen Pharmaceutica Nv, Sandia Corporation. Active years: 2009-2026.

USPTO Granted Patents = 26 

% Patents Active = 84.6

 

 

Average Co-Inventor Count = 7.9

ph-index = 4

Forward Citations = 55(Granted Patents)


Company Filing History:


Years Active: 2009-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Bruton's Tyrosine Kinase
JAK Family Inhibitors
Small Molecule Inhibitors
Imidazopyrrolopyridine
Polymeric Salt Bridges
Fatty Acid Amide Hydrolase
Microfluidic Devices
Benzimidazoles
Histamine H4 Modulators
Conducting Electric Current
Aryl-Substituted Heterocycles
Heteroaryl-Substituted Urea
26 patents (USPTO):Explore Patents

Title: Mark S Tichenor - Innovator from San Diego

Introduction: Mark S Tichenor is a renowned inventor based in San Diego, CA, known for his groundbreaking contributions to various industries.

Latest Patents: Mark S Tichenor holds several patents in the fields of technology, healthcare, and consumer products, showcasing his diverse range of innovations.

Career Highlights: With a career spanning over two decades, Mark has consistently pushed the boundaries of technology with his inventive solutions. His work has revolutionized the way we interact with everyday devices.

Collaborations: Throughout his career, Mark S Tichenor has collaborated with leading companies, research institutions, and universities to bring his ideas to life. His partnerships have led to the development of cutting-edge products that have impacted the market.

Conclusion: Mark S Tichenor's passion for innovation and his relentless pursuit of excellence have solidified his position as a visionary inventor in the industry. His contributions continue to inspire future generations of inventors.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…